Clinical Trial Update: Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated different doses of S-adenosyl-L-methionine (SAMe) in individuals with nonalcoholic fatty liver disease, with results posted in 2016. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• SAM-e (S-adenosyl-L-methionine)

Snippet

Sponsor: Abbott | Conditions: Non Alcoholic Fatty Liver Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-02-19